In the trial of 1,961 adults without TD2M, who had either a body mass index (BMI) of 30 or more, or a BMI of 2729 and at least one comorbidity, those taking semaglutide achieved an average of 14.9% body weight loss at 68 weeks, compared with 2.4% in those who received placebo
article are helpful next reads.
Liu Y, Li P, Lu J, Xiong W, Oger J, Tetzlaff W, et al
Ozempic (Semaglutide GLP-1) is an agonist of the GLP-1 receptor, a type of medication that mimics the incretin hormones in the body, which are released after eating
This water weight is not fat gain
This litigation is not technically a class action but has been consolidated into a Multidistrict Litigation (MDL) in the United States District Court for the Eastern District of Pennsylvania